ArticleJHEP reports : innovation in hepatology2025
The 'social gradient' in primary liver cancer in France: A national observational study.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Social deprivation has been associated with primary liver cancer (PLC); however, its impact on access to curative treatment and survival remains uncertain. We assessed the effect of deprivation on healthcare access and evaluated whether care centralization could improve PLC management at a national level. Methods: We conducted a retrospective longitudinal cohort study using the French National Discharge Database (2017-2021), including all adult patients with PLC. Deprivation was the primary exposure. Primary and secondary outcomes were access to curative treatment (surgery, transplantation, or ablation) and mortality. Associations were assessed using adjusted odds ratios (aORs) and hazard ratios (aHRs) derived from random-effects logistic and Cox models, clustered by French regional departments. G-computation was applied to estimate the absolute effect of centralization (treatment within referral hospitals) on curative treatment access among deprived patients. Results: Among 62,351 patients (median age [IQR], 71 [63-78] years; 70.8% male), 45% (n = 27,872) were classified as deprived. Deprivation was associated with reduced access to curative treatment (aOR 0.89; 95% CI 0.85-0.92; Conclusions: Deprivation reduced access to curative treatment and increased mortality among patients with primary liver cancer in France. Care centralization could help mitigate these disparities and improve outcomes. Impact and implications: Social deprivation is known to increase the risk of developing primary liver cancer (PLC) and to reduce survival. However, it has been unclear if this is due to late-stage diagnoses or limited access to treatments, as earlier studies mostly considered factors like race, ethnicity, sex, and insurance status. Our study highlighted that socially deprived patients with PLC in France face reduced access to curative and palliative treatments, resulting in lower overall survival rates. A key finding was that the negative impact of social deprivation was mitigated by care centralization - when patients were diagnosed or treated in referral centers, social deprivation no longer influenced access to curative treatments or mortality outcomes. These findings support the need for centralized PLC management strategies across the country to improve care outcomes for socioeconomically disadvantaged individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.